Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model

• Автори: Philip J. Kuehl (Автор), Marcie J. Grimes (Автор), Devon Dubose (Автор), Michael Burke (Автор), David A. Revelli (Автор), Andrew P. Gigliotti (Автор), Steven A. Belinsky (Автор), Mathewos Tessema (Автор)
• Формат: Книга
• Опубліковано: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Intravenous (IV) topotecan is approved for the treatment of various malignancies including lung cancer but its clinical use is greatly undermined by severe hematopoietic toxicity. We hypothesized that inhalation delivery of topotecan would increase local exposure and efficacy against lung cancer whi...